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Abstract 
 
Leishmaniasis, one of the highly neglected diseases is currently a significant health problem in northern 
Africa with a rising concern in western Africa because of co-infection with the Human Immunodeficiency Virus 
(HIV). In this review, we present a summarized analysis of the epidemiology, infective species, parasites reservoirs, 
diagnosis, treatment and control measures of leishmaniasis in northern and western Africa region. In northern Africa, 
the disease is prevalent in Morocco, Algeria, Tunisia, Egypt and Libya. Comparatively, there are low prevalence 
rates of the disease in West African countries including Cameroon, Ghana, Burkina Faso, Niger, Mali, Nigeria and 
Senegal.  In North Africa, visceral leishmaniasis (VL) is caused by L. infantum and transmitted by Phlebotomus 
perniciosus and P. longicuspis.  On the other hand, cutaneous leishmaniasis (CL) is mainly caused by L. major and 
transmitted by P. papatasi, P. duboscqi and P. pedifer with L. infantum and L. tropica causing lower incidences of 
the disease. Notably, Algeria is one of the countries that constitute 90% of CL cases worldwide. In Western Africa; 
CL is caused by L. major while VL is caused by L. donovani. In these regions, zoonotic and anthroponotic cutaneous 
and visceral leishmaniasis is a health problem that should be addressed urgently.  
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Introduction 
 
Leishmaniasis is a zoonotic infection that is caused by obligate intracellular protozoa of the genus 
Leishmania. Natural transmission of Leishmania parasites is carried out by sandflies of the genus 
Phlebotomus (Old World) or Lutzomyia (New World) (Mandell et al. 2005). Leishmania parasites cause 
three forms of leishmaniases according to the localization of the parasites in mammalian tissues, notably 
visceral, cutaneous, and mucosal leishmaniasis. The outcome of infection depends on the species of 
Leishmania parasites and the host’s immune responses (Roberts, 2006). Visceral leishmaniasis (VL) is the 
most severe form of leishmaniasis involving internal organs such as the spleen and liver and is fatal if left 
untreated (Mauel, 2002).  
On a global scale, approximately 350 million people live in areas of active transmission of 
Leishmania, with 14 million people throughout Africa, Asia, Europe, and the Americas directly affected by 
the disease (WHO, 2006). The global burden of leishmaniasis has remained stable for some years, causing 
a morbidity and mortality loss of 2.4 million disability adjusted life-years (DALYs) and approximately 
70,000 deaths, a significantly high rank among communicable diseases (Davies et al. 2003; Reithinger et al. 
2007). 
Leishmania and Human Immunodeficiency Virus (HIV) co-infection has surged as a major 
complication of leishmaniasis and has ignited calls for the recognition of leishmaniasis as an Acquired 
Immunodeficiency Syndrome (AIDS) defining illness (Singh, 2006). In Africa, particularly Ethiopia and 
Sudan, it is estimated that 70% of adults with VL also have HIV infection (Desjeux, 2001).  
In West Africa, the disease has been reported in Niger (Stevene, 1911), Mali (Lefrou, 1948), 
Nigeria (Dyce-Shar, 1924), Senegal (Riou. and Advier, 1933), Cameroon, Burkina Faso, Mauritania, 
Gambia and Guinea (Boakye et al. 2006). 
In northern Africa, Algeria is one of the eight countries that constitute 90% of CL in the World 
(Desjeux, 2004). Leishmaniasis contributes significantly to the propagation of   poverty, because treatment 
is expensive and hence either unaffordable or it imposes a substantial economic burden, including loss of 
wages (WHO, 2006. Current control measures against leishmaniasis rely on chemotherapy to alleviate 
disease and on vector control to reduce transmission. To date, there is no vaccine in routine use against 
leishmaniasis (Handman, 2001).  
This review article is based on information from bibliographic research, PubMed and MEDLINE 
searches, review articles and papers in their reference lists on leishmaniasis with several key words such as 
‘‘leishmaniasis”, “cutaneous”, “diffuse cutaneous”, “mucosal”, ‘‘mucocutaneous’’ and “visceral 
leishmaniasis”; “kala azar” for recent clinical and basic science articles related to leishmaniasis in northern 
and western Africa. 
 
 
Leishmaniasis in North African region 
 
Zoonotic cutaneous leishmaniasis caused by Leishmania major and L. tropica is found in many 
countries of North Africa. Cutaneous leishmaniasis caused by L. major is distributed in a belt from 
Marrakech and Casablanca in Morocco through Algiers in Algeria, Tripoli in Libya to Cairo, Alexandria 
and to the Sinai in Egypt. On the other hand, CL due to L. tropica (“dry sore”) is also distributed in a 
similar belt across North Africa from the Canary Islands to Egypt. It is widespread in the urban areas of 
these countries although L. tropica is becoming more common in rural highland villages. CL is an 
important health problem, with clinical manifestations varying from simple cutaneous to mucocutaneous 
and disseminated lesions. Phlebotomus papatasi (sandfly) is the proven vector of L. major, and rodents 
Psammomys obesus and Meriones spp. serve as animal reservoir hosts. Some countries of the region have 
endemic foci of zoonotic and anthroponotic cutaneous leishmaniasis, which could cause epidemics among 
non-immune populations if they are involved in the transmission cycle (Ben Salah et al. 1995).  
 
Leishmaniasis in Morocco 
 
Morocco lies in the Mediterranean region where leishmaniasis is prevalent. Both CL and VL have 
been reported.  During the past 20 years, CL has emerged as a major public health threat in Morocco 
(Rhajaoui et al. 2007). Cutaneous leishmaniasis caused by L. major has been reported in Morocco since 
1914 (Rioux et al. 1986).  In this country, CL is caused by L. major or L. tropica while VL is caused by L. 
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infantum (Rhajaoui,  et al., 2004; Boussaa et al.,  2005).  The dog was confirmed to be the main reservoir of 
L. infantum MON-1, while the reservoir of L. infantum MON-24, causative agent of both infantile VL and 
CL, has not yet been identified (Haralambous et al. 2007). Until recently, CL was largely confined to arid 
Saharan regions (Haralambous et al. 2007).   The Ministry of Health in Morocco considers L. tropica as a 
significant health threat. In 2001, the Moroccan Ministry of Health (MMH) reported 2,028 CL cases caused 
by L. major and L. tropica (Haralambous et al. 2007).   Leishmania tropica CL has been reported in Azilal, 
Essaouira, Taza, Fes, the province of Chichaoua, and central Morocco (Marty et al. 1989; Rhajaoui et al. 
2004).  The northern coastal regions of Morocco are endemic for human and canine VL. As in other VL-
endemic regions surrounding the Mediterranean Sea, this disease is caused by L. infantum (Ashford, 2000).  
In Morocco, the only previous human CL case caused by L. infantum was reported in 1996, within an 
active focus of VL (Rioux et. al. 1986, 1996).  Cutaneous leishmaniasis and VL overlap in many provinces 
of central Morocco; anthroponotic foci of L. tropica CL are found in Fes and Taza (Guessous-Idrissi et al 
1997; Chiheb et al. 1999; Rhajaoui et al. 2004) not far from existing VL foci including Sidi Kacem.  
Furthermore, several cases of canine VL caused by L. tropica have been reported in regions where canine 
VL is caused by L. infantum (Rhajaoui et al. 2007).   
The overlapping distribution of parasite species, causing diseases with similar clinical pictures, 
demonstrates the need for additional epidemiologic and ecologic studies of CL in conjunction with species 
identification. This is especially important as opposed to traditional methods of determining infection from 
patient history and microscopy (Rhajaoui et al. 2007). In Morocco, local physicians and healthcare 
administrators often do not realize that different species of Leishmania require differential treatments, 
which can result in a failure to diagnose more serious disease. A simple, sensitive polymerase chain 
reaction (PCR) test could easily reduce such risk. One of the emerging threats is recurrent failure of local 
treatments (paromomycin and intralesional sodium stibogluconate) against L. tropica (Blum et al. 2004).  
 
Leishmaniasis in Libya 
 
Visceral leishmaniasis is an important public health problem in Libya, but until 1992, its exact 
prevalence was unknown (Mehabresh and El-Mauhoub, 1992). In addition, the cases of VL in Libya that 
have been reported for over 80 years were all from the northern coastal areas near Tripoli and the Green 
Mountain area. However, since 1985, there have been new cases of the disease from the southern part of 
Libya in the Saharan and sub-Saharan areas, an area 250 km to the south-west of Sabha. This southern area 
has recently undergone much agricultural organization with increasing water supply and other 
environmental changes, which may be partially responsible for the establishment of these new foci. Twenty 
patients with hepatosplenomegaly and fever were referred from that area to the El-Fateh Children's 
Hospital in Benghazi for investigation. All had the clinical features and laboratory data indicative of the 
Mediterranean type of the disease. All were treated with sodium stibogluconate (10 mg kg-1 day-1), and 
responded well to this regime (Mehabresh, 1994).  
A review of the records of 21 children treated at El-Fatah Children's Hospital, Benghazi between 
March 1982 and May 1990 demonstrated that the commonest presenting features were fever, abdominal 
distension, and anorexia with weight loss, hepatosplenomegaly and pallor. The consistent laboratory 
findings were aneamia with reticulocytosis and normal serum iron, neutropenia, thrombocytopenia, high 
erythrocyte sedimentation rate (ESR) and hyperglobulinaemia. The bone marrow was positive for L. 
donovani in 86% of cases and the indirect haemagglutination test was positive in all patients. 
Bronchopneumonia was the most common complication and responded rapidly to antibiotics. All patients 
were treated with sodium stibogluconate 10 mg/kg/day. There were no major side-effects or complications 
of drug therapy. The relative paucity of cases and their late presentation may reflect a lack of awareness of 
the occurrence of visceral leishmaniasis by doctors in the community (Mehabresh and El-Mauhoub, 1992). 
Cutaneous leishmaniasis is widespread in the north-western region of the Libyan Arab Jamahiriya 
(El-Buni et al. 2000). The first two cases of CL were recorded in 1930 (Onorato, 1931). Another 40 cases 
were recorded in Nalut near the Tunisian border (Kadiki and Ashraf, 1971). Several CL cases have been 
recorded west and south-west of Tripoli among residents and new settlers in towns, villages and 
agricultural projects (El-Buni et al. 2000). 
In the Yafran area of Libya, P. papatasi was the most common sandfly species found, followed by 
P. sergenti. Wild rodents including Meriones libycus, M. shawi and Gerbillus gerbillus have been found in 
the studied area and are considered possible animal reservoirs (El-Buni et al. 2000).    
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Leishmaniasis in Tunisia 
 
Various forms of leishmaniasis are recurring in Tunisia, posing numerous problems concerning 
their aetiology and their clinical and epidemiological aspects which vary according to region. The 
respective role and importance of the animal hosts as well as that of the vectors involved is not yet clear, 
especially where, in recent years, important ecological changes especially construction of hydroelectric 
dams have taken place.  
Three clinico-epidemiological forms of cutaneous leishmaniasis exist in Tunisia: zoonotic 
cutaneous leishmaniasis (ZCL; epidemic in the centre and the southwest); sporadic cutaneous leishmaniasis 
(SCL; found in the north); and chronic cutaneous leishmaniasis (CCL; originally described from Tataouine, 
in the southeast) (Kallel et al. 2005). Zoonotic CL is caused by L. major, SCL by L. infantum and CCL by 
L. tropica (Kharfi et al. 2003). 
Recent studies by Ghrab et al. (2006) on vectors of leishmaniasis showed the dominance of 
subgenus Larroussius species in northern foci, P. papatasi in south-western foci and their co-dominance in 
the centre of the country in accordance with the distribution of L. infantum and L. major in Tunisia. These 
studies indicated that in L. infantum areas, the dominant species were respectively: P. perfiliewi in the 
cutaneous leishmaniasis site of the humid bioclimatic stage, P. perniciosus in the cutaneous and visceral 
leishmaniasis foci of semi-arid and arid bioclimatic stages and P. longicuspis in the visceral leishmaniasis 
focus of Saharan bioclimate.  
In the ZCL foci, P. papatasi was a dominant species. In the well-known south-eastern foci of 
cutaneous leishmaniasis due to L. killicki, P. sergenti was a dominant species with P. perniciosus while in 
the central emerging foci of L. killicki; P. perniciosus was a dominant species in some sites whereas it was 
very rare in others. In these sites, the subgenus Paraphlebotomus was always present with a higher 
abundance of P. alexandri than P. sergenti. Rodents Psammomys obesus and Meriones spp. serve as animal 
reservoir hosts of L. major (Ghrab et al. 2006). 
Zoonotic CL in Tunisia is characterized by clinical polymorphism (Masmoudi et al. 2007). 
Besides the classical forms (ulcerated and crusted form), other clinical forms seen in Tunisia are the lupoid, 
loco regional spreading (sporotrichoid form, satellite papules). Some atypical forms can be found which are 
due to variation of host immune responses and to the strain of the parasites involved. 
The different forms of CL in Tunisia are treated with the same protocol (Chargui et al. 2005). In 
addition, a study on the efficiency of a polymerase chain reaction (PCR) method in establishing the 
diagnosis of CL in Tunisian patients supported the incorporation of PCR into diagnostic strategies for CL 
in the country (Chargui et al. 2005). The first three documented cases of anthroponotic cutaneous 
leishmaniasis due to Leishmania killicki were recently reported from locations outside the original focus of 
Tataouine in southeast Tunisia. Three strains were isolated from three patients from Gafsa, Sidi Bouzid and 
Seliana indicating an extension of this parasite's range towards the centre and the north of Tunisia (Haouas 
et al. 2005). 
Whereas mucocutaneous leishmaniasis endemic in Central and South America are due to L. 
braziliensis and provokes mutilating and disfiguring lesions, the form in Tunisia is caused by L. major, is 
dermotropic and is characterized by the absence of mutilating lesions. In addition, MCL in the New World 
differs from that in Tunisia in that it is refractory to treatment while that in Tunisia responds excellently to 
treatment (Kharfi et al. 2003). A randomized, placebo-controlled trial in Tunisia treating CL with 
paromomycin ointment did not indicate any difference between treatment and control groups suggesting 
that paromomycin ointment should not be used in the present formulation as a treatment for ZCL in Tunisia 
(Ben Salah et al. 1995). 
According to Kamarianakis (Kamarianakis et al. 2007), there are several reasons behind the 
increased ZCL incidence in the region. The majority of them depend on human activities such as 
environment modifications, resettlement of non-immune populations or development of agro-industrial 
projects, military activities, and urbanization and so on. Environmental modification, such as construction 
of dams, can change the temperature and humidity of the soil and vegetation, which may result in changes 
in the composition and density of sandfly species as well as changes in populations of rodent species. The 
formation of new settlements with non-immune populations facilitates the outbreak of leishmaniasis. For 
example, the outbreak of ZCL in the central and southern governorates of Tunisia in 1982-83 occurred 
following the construction of the Sidi Saad Dam (Kamarianakis et al. 2007). On the other hand, the 
destruction of Psammomys obesus burrows by deep ploughing, removal of chenopods and planting of trees 
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in a 2-3 kilometer zone surrounding human settlements has resulted in a significant reduction of the 
incidence of cutaneous leishmaniasis among the local human population (Kamarianakis et al. 2007). 
 
Leishmaniasis in Algeria 
 
As in other countries of Africa where leishmaniasis is prevalent, both VL and CL have been 
reported in Algeria (Harrat et al. 1996). The Grande Kabylie region of Algeria appears to be the most 
important focus of VL in North Africa and the Mediterranean region (Dedet et al. 1977). In Algeria, the 
incidence of hospital diagnosed VL has increased dramatically in recent years (Regional Disease Vector 
Ecology Profile, North Africa, 2000). About 500 cases were recorded between 1965 and 1974. Between 
1985 and 1990, a resurgence of VL was observed with 5 human cases per 100 000 annual prevalence and a 
6 per cent death rate in the region (Harrat et al. 1996). During this period, there were 1,122 cases, the 
majority of which were in the region of Tisi-Ouzzou in the Greater Kabylia. This increase was attributed to 
the cessation of insecticide spraying as part of the malaria control program. A small number of cases have 
been identified in Algiers (Regional Disease Vector Ecology Profile, North Africa, 2000).  
Two forms of CL are endemic in Algeria. Zoonotic CL caused by L. major is widespread in the 
steppe regions of the northern Sahara while sporadic CL caused by L. infantum occurs in the north along 
the coastline (Benikhlef et al. 2004). The main causative agent for the sporadic form is L. infantum 
zymodeme MON-24. It has been isolated from the sandfly vector P.  perfiliewi and the main reservoirs are 
dogs. Recently, L. infantum MON-24 was first isolated from a dog (Benikhlef et al. 2004).  
In Algiers, the number of cases of canine leishmaniasis has been shown to be on the rise with a 
frequency of 35%. Human leishmaniasis was also shown to be on the rise, with 22 cases of VL and 40 
cases of CL being noted in the period between 1990-1997 (Harrat and Belkaid, 2003). 
 
Leishmaniasis in Egypt 
 
Both VL and CL occur in Egypt although the prevalence is relatively low (Mohareb et al. 1996).  
Visceral leishmaniasis due to L. infantum was not confirmed in Egypt until 1983. It is primarily a disease of 
rural populations, but in some areas urban transmission exists. The disease has been found near Alexandria, 
in El Agamy (Awadalla et al. 1987). On the other hand, VL due to L. donovani is less frequent and is 
usually imported from Sudan (Mohareb et al. 1996). The proven or suspected vectors of L. infantum are P. 
ariasi, P. longicuspis, P. pernicious, P. perfiliewi and P. langeroni (Regional Disease Vector Ecology 
Profile, North Africa, 2000).  
In Egypt, CL has primarily been identified in northern Sinai (Mansour et al. 1987) and was 
attributed to L. major, according to isoenzyme analysis (Mansour et al. 1989). A longitudinal 
epidemiologic study of CL transmission conducted between July 1989 and June 1991 in a 1,200-sq km 
sector of the north eastern Sinai Desert revealed that L. major was the only Leishmania species isolated 
from human, sand fly, and wild rodent (Gerbillus pyramidum) (Fryauff et al. 1993).   
There are few endemic ZCL cases in the Sinai and Suez Canal Governates in Egypt. A survey of 
new cases of human ZCL among outpatients complaining of skin disorders revealed 16 cases out of 100 
individuals examined. None of the 50 normal individuals had latent infections. Isolates from 3 individuals 
were identified as L. major Zymodeme London 70 (Hamadto et al. 2003). 
 
 
Leishmaniasis in West Africa 
 
Visceral leishmaniasis, CL and MCL have been reported in West Africa (Boakye et al. 2006). The 
first case of leishmaniasis in the region was reported in Niger in 1911 (Stevene, 1911), followed by other 
reports from Nigeria (Dyce-Shar, 1924), Senegal (Riou and Advier, 1933) and Mali (Lefrou, 1948). Other 
countries that have reported cases in the past include Cameroon, Burkina Faso, Mauritania, Gambia and 
Guinea (Boakye et al. 2006).  
In the West African region, CL is caused by L. major and has been reported from reservoir hosts, 
vectors and human patients from The Gambia, Senegal, Burkina Faso and Mali (Dedet et al. 1981, 1982; 
Izri et al. 1989; Harrat et al. 1998). Cutaneous leishmaniasis is proposed to be endemic in a belt running 
from Mauritania, Gambia and Senegal in the west to Nigeria and Cameroon in the east. Although the CL 
belt mentioned cuts across the northern part of Ghana, the disease has not been reported in the country until 
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recently, in 1999, when some chronic ulcers diagnosed as cutaneous leishmaniasis were observed in the Ho 
District of the Volta Region (Boakye et al. 2006). Recently, the first definitive evidence of human CL 
resulting from L. major infections in Ghana was reported in Ho District (Fryauff et al. 2006). On the other 
hand in Ouagadougou, the capital city of Burkina Faso, 1,845 people were diagnosed with CL between 
1996 and 1999 (Traoré et al. 2001). 
Cases of MCL are reported to be rare in West Africa (Boakye et al. 2006). However, two cases of 
cutaneous leishmaniasis with mucous membrane involvement were reported in Senegal (Strobel et al. 
1978). Like in other parts of Africa and the Old World, the causative agent of VL in West Africa is L. 
donovani (Bryceson, 1996). The disease however, is uncommon. Visceral leishmaniasis cases have been 
reported from Togo (De Campos et al. 1979), Burkina Faso (Andre et al. 1978) and the Gambia (Conteh 
and Desjeux, 1983; Greenwood et al. 1984). 
It has been observed that all the L. major strains isolated from Senegal were identical to those 
from Central Asia (Dedet et al. 1982). However, the zymodeme found in Burkina Faso was different from 
that from Mali and Senegal (Izri et al. 1989). Most other reports including those from Ghana have indicated 
the presence of amastigotes in human samples but have not identified the specific Leishmania parasites 
(Boakye et al. 2006).  
In West Africa, the reservoir hosts for L. major have been identified only from Senegal and The 
Gambia (Dedet et al. 1981; Dedet et al. 1982; Blanchot et al. 1984).  The rodents Mastomys erythroleucus, 
Tatera gambiana, Arvicanthis niloticus and Mastomys erythroleucus and the dog  are the reservoir hosts in 
the Gambia (Boakye et al. 2006). 
 
Leishmaniasis in Cameroon 
 
Both VL and CL have been reported in Cameroon. Cutaneous leishmaniasis prevails mainly in the 
northern part of the country, in the area of Mokolo, areas bordering Chad (including N’Djamena), and the 
eastern parts of the country whereas VL is more frequent in the area of Kousseri, in the north-east (Donji et 
al. 2001). Cutaneous leishmaniasis has been prevalent in Cameroon since 1930 (Hervé, 1937). Since then, 
there has been an upsurge in the number of CL cases that have been recorded (Donji et al. 2001). On the 
other hand, VL was first reported by Djibrilla et al. in 1979. However, few studies have focused on VL in 
Morocco, and the disease is still very little known even by medical staff and the final diagnosis is 
established only late and sometimes patients die without specific treatment. Between October 1987 and 
January 1988, a study conducted in the Kousseri region of the country found that out of 120 individuals 
who were sampled, 46 of them exhibited symptoms of leishmaniasis and 9 were confirmed positive for VL 
based on parasitological and serological diagnosis (Kaptue et al. 1992).  
In Cameroon, L. major transmitted by P. duboscqi has been identified as the causative agent of CL 
while VL is caused by L. donovani (Donji et al. 2001). However, several gaps still exist about the 
epidemiology of leishmaniases in Cameroon; the prevalence of the disease in the population of endemic 
foci, identifying new foci probably in the southern forest, the repertoire of these parasitic species, vectors, 
animal reservoirs, natural factors and contributors to the spread of the disease. These data are deemed 
essential in planning a program against this emerging public health problem. Their availability will allow a 
better appreciation of risk of outbreaks and thereby limit the impact of the disease on the health of the 
population. Such studies ought to be accompanied by training of medical staff and paramedics on the 
different diagnostic methods (clinical, parasitological, immunological serum) and therapeutic especially in 
VL (Donji et al. 2001).  
 
Leishmaniasis in Ghana 
 
Since 1999, an increasing number of suspected CL cases have been reported from the southern 
Volta Region of Ghana in a moist semi-deciduous forest ecosystem where such skin lesions had not been 
previously reported. The assumption of CL was based subjectively on local microscopy, which identified 
Leishmania amastigotes in skin lesion biopsies taken from a cluster of local patients. Between 1999 and 
2002, the Ghana Health Service recorded 2,426 suspected cases of CL in the Ho, Hohoe, and Kpando 
Districts (2,348, 2, and 76 cases, respectively). In 2003, the number of suspected cases rose to 6,450 (6,185, 
174, and 91 in the same respective districts) with 116 villages affected (Fryauff et al. 2006). A limited 
survey of towns in the Ho district during 2002 identified suspected CL lesions in 12.2–32.3% of local 
school children. 
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Microscopic dissection and examination of 722 individual female sand flies captured in light traps 
during an epidemiological survey in the Ho District revealed no Leishmania infections. Although the study 
considered P. duboscqi as the primary suspected vector of CL, the species was near the least abundant of 
17 different sand fly species that were collected and comprised only 0.1% of the total catch. One other 
suspect sand fly species, P. rodhaini, was captured for the first time in Ghana, but at similarly low numbers 
(0.3%), insufficient to yield a profile of seasonal abundance (Fryauff et al. 2006). 
 
Leishmaniasis in Burkina Faso 
 
Burkina Faso is a western African country with a high prevalence of both HIV and leishmaniasis 
infections (Niamba et al. 2007). Cutaneous leishmaniasis is caused by L. major MON-26 and clinical 
symptoms include papules, nodules, ulcers or papulo-ulcerative lesions (Heid, 1999). To date, no VL cases 
have been reported in Burkina Faso. Diffuse cutaneous forms of leishmaniasis are uncommon in Burkina 
Faso. However, a DCL case masquerading as leprosy in the context of HIV co-infection was recently 
reported (Niamba et al. 2007). 
 
Cutaneous leishmaniasis in Senegal 
 
A case of infiltrated cutaneous leishmaniasis and sporothricoid due to L. major MON-74 has been 
reported in Senegal (Thierno et al. 2001). In addition, DCL has been reported in this country (Develoux et 
al. 1996).  
 
 
Control of leishmaniasis in Northern and western Africa 
 
Leishmaniasis is one of the most neglected tropical diseases, in terms of the few tools available for 
control and the lack of clear criteria for methods of control (WHO, 2006). The main control strategy of 
leishmaniasis is case finding and treatment plus, when feasible, vector control and in zoonotic foci, animal 
reservoir control (Neouimine, 1996; WHO, 2004). So far, there is no effective vaccination against human 
leishmaniasis, and control of this disease relies primarily on chemotherapy (Handman, 2001). Pentavalent 
antimony has long been the pillar of anti-Leishmania chemotherapy, and although resistance to this class of 
drug has not been reported in Africa, the situation in northeast India has reached epidemic proportions 
(Croft et al. 2006). However, the main shortcoming arises from the fact that the pentavalent antimonials are 
costly, toxic, and require long duration of treatment and hospitalization.  In addition, second-line drugs 
(pentamidine and amphotericin B) are limited by toxicity and availability, and newer formulations of 
amphotericin B are not affordable (Guerin et al. 2002).  The high cost of drugs results in interruption of 
treatment with the possibility of development of chronic debilitating forms of the disease (Desjeux, 1992).  
Paromomycin ointment has been tried for the treatment of cutaneous leishmaniasis in Tunisia although 
results suggest that the formulation of the ointment needs further improvement before this method can be 
recommended for field practice (Ben Salah et al. 1995). International and voluntary organizations greatly 
support national control programmes with antileishmanial drugs, especially in emergencies (Neouimine, 
1996). 
Demonstration of parasites in stained smears of tissue aspirates from the spleen, bone marrow, or 
lymph node is the gold standard for diagnosis of VL with splenic aspirate and bone marrow being more 
superior to lymph node (Hailu et al. 2005). However, difficulties in obtaining and examining tissues mean 
that serological methods based on the detection of specific humoral antibodies are increasingly being used. 
The direct agglutination test (DAT), in which stained parasites are agglutinated by serum antibodies, is 
popular in Africa, but variation between batches and the high cost of commercially available antigen are 
limiting factors (Davies et al. 2003). In the Indian subcontinent, but less so in Europe and Africa, a rapid 
strip test is used to detect antibody to rK39 is both sensitive and specific. Weak responses in some patients, 
persistence of antibodies after cure, and presence of antibodies in some healthy individuals are inherent 
limitations with antibody based diagnostics. Techniques based on PCR are potentially highly sensitive and 
specific, but they need to be adapted for field use in terms of cost and user skills (Davies et al. 2003). 
On vector control, sandflies are still very sensitive to insecticides (WHO, 2004).  A recent study in 
Sudan indicates a potentially strong reduction in VL incidence following a community distribution of 
Insecticide Treated Nets (Ritmeijer et al. 2007). Further studies indicated that the use of impregnated bed 
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nets and going to bed early could provide a high degree of personal protection against this VL (Elnaiem et 
al. 1999). However, the potential use of bed nets for sandfly control in northern and western Africa is 
complicated by the fact that during the hot season it is considered too hot to sleep under the fine-mesh nets, 
which cut down ventilation (Ritmeijer et al. 2007). Furthermore, during the dry season people prefer to 
sleep outdoors and may be reluctant to use nets due to the daily routine to set up the nets before going to 
bed. In these resource restrained countries, vector control by spraying houses with insecticide is not 
sustainable due to logistic constraints and high cost.  
Similarly, animal reservoir control through environmental management is expensive and difficult 
to implement; the efficacy of dog culling is questionable.  In spite of this, in Tunisia, the destruction of 
Psammomys obesus burrows by deep ploughing, removal of chenopods and planting of trees in a 2-3 
kilometre zone surrounding human settlements has resulted in a significant reduction of the incidence of 
cutaneous leishmaniasis among the local human population (Kamhawi, 1993). This is worsened by the lack 
of well-trained technical personnel and weak delivery systems, political and financial commitments are low 
and the level of implementation is frequently low (WHO, 2004).  
Due to the apparent neglect of leishmaniasis in West Africa, there is no organized control effort in 
this region except during outbreaks when chemotherapeutic treatment is administered to those showing the 
disease (Boakye et al. 2006).  In spite of   the documented effectiveness of vector control with insecticides, 
and its potential in reducing disease incidence this has not been practiced in West Africa. In view of this, 
intensified collaboration between countries is essential in order to establish surveillance sites, map foci and 
prevalence on the basis of epidemiological assessments, train technical staff, investigate treatment failures, 
and set up computerized systems for data collection and analysis (WHO, 2007). The most pressing research 
needs for leishmaniasis control are the search for alternative and cheap medicines for oral, parenteral or 
topical administration in shorter treatment cycles, and identification of mechanisms to facilitate access to 
existing control measures including health sector reform in some developing countries (WHO, 2007).  
 
Conclusions 
 
Although VL is relatively rare in West Africa as compared to the CL, the disease is spreading to 
previously non-endemic areas and there is need for integrated control strategies to curb this wave. Of 
particular concern is the emerging Leishmania-HIV co-infection in West Africa which complicates 
treatment of the disease. Research into novel control measures is limited and this is compounded by the 
limited availability of data on prevalence of leishmaniasis. Consequently, there is need to establish a 
surveillance system to monitor the spread of the disease. 
The number of leishmaniasis cases in Tunisia is increasing mostly because of human activities 
such as environment modifications, resettlement of non-immune populations or development of agro-
industrial projects, military activities, and urbanization.  
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